CN111393404B

CN111393404B - Benzothiophene compounds, and pharmaceutical composition and application thereof

Info

Publication number: CN111393404B
Application number: CN201910002427.8A
Authority: CN
Inventors: 张翱; 耿美玉; 丁春勇; 谢作权; 张燕; 沈安成; 王玺渊
Original assignee: Shanghai Institute of Materia Medica of CAS
Current assignee: Shanghai Institute of Materia Medica of CAS
Priority date: 2019-01-02
Filing date: 2019-01-02
Publication date: 2023-02-17
Anticipated expiration: 2039-01-02
Also published as: CN111393404A

Abstract

The invention relates to benzothiophene compounds, and a pharmaceutical composition and application thereof. Specifically, the compound has a structure shown in a formula I, wherein the definition of each group and substituent is described in the specification. The invention also discloses a preparation method of the compound and application of the compound in the aspect of tumor resistance.

Description

Benzothiophene compounds, and pharmaceutical composition and application thereof

Technical Field

The invention relates to the field of medicines, and particularly relates to benzothiophene compounds, and pharmaceutical compositions and applications thereof.

Background

Interferons (IFNs) are a family of multifunctional cytokines with antiviral, antiproliferative and immunomodulatory activities, the chemical component of which is a glycoprotein. Depending on the binding receptor, it can be classified into type I, type II and type III, which are key components of the body's natural immune system. Among them, type I interferons (mainly alpha/beta interferons) are closely related to the pathology and clinical manifestations of various diseases, including infectious diseases, viral infections, cancer, autoimmune diseases, etc. In recent years, the relationship between IFN and tumor has been particularly attracting attention.

Signaling of innate immunity by the Tumor Microenvironment (TME) is a critical step in the activation of tumor-specific T cells and infiltration of tumor-infiltrating lymphocytes (TILs). Among them, type I IFNs play a key role in tumor-activated T cell activation. The induction of I-type interferon gene expression plays an important role in natural immune signal path, and can activate immunostimulating cells including dendritic cells, change tumor microenvironment, activate adaptive immune system through a series of cascade reactions, induce and activate the generation of tumor specific T cells, and further kill tumor cells. Therefore, promoting the induction of the expression of type I interferon genes becomes a research strategy with great potential in the field of anti-tumor immunity.

For example, the normal activation of cyclic guanosine monophosphate synthetase (cGAS) signal path can not only induce the production of type I interferon and other cytokines, activate T cells targeting tumors, but also trigger the immune response of the body to tumor cells, and further enhance the efficacy of radiotherapy for tumors, for example, cGAS can sense DNA released by killed tumor cells to activate interferon gene stimulating protein, so as to induce dendritic cells to produce type I interferon, further activate potential anti-tumor immune response, and enhance the efficacy of radiotherapy.

In addition, the activated interferon gene-stimulating protein shows a certain potential in combination with other immune checkpoint inhibitors. Although two monoclonal antibody drugs against the immune checkpoint PD-1/PD-L1 have been successfully marketed at present, the overall efficacy of these drugs is relatively low, only about 20-30%. PD-1/L1 inhibitors can relieve the activation inhibition of T cells, but if T cells are not present in/near the tumor, the drugs are also difficult to exert therapeutic effects, which is also part of the reason for the low overall efficiency of the drugs. Thus, patients need to have an immune response before using such drugs so that checkpoint inhibition can be effective. The innate immune system is just able to accomplish this task. Thus, activation of the interferon gene stimulates protein, induces production of type I interferon, and thereby provides a basis for T cell activation and proliferation, and then the checkpoint inhibitor is used to allow the T cells sufficient capacity to eliminate tumor cells in vivo.

In conclusion, activating the interferon gene to stimulate protein and inducing the generation of type I interferon becomes a potential research direction in the field of anti-tumor immunity. The interferon gene stimulating protein agonist which is reported to be effective to both human and murine sources at present is mainly Cyclic Dinucleotide (CDN) compounds, for example, ADU-S100 has entered into the first clinical research, but the compounds have complex structures and are not easy to synthesize, more importantly, the defects of unstable metabolism exist, and the like, so that the administration mode of the medicine is mainly intratumoral injection at present, and the clinical application of the medicine is greatly limited.

Therefore, there is a need for further development of novel small molecules with simple structure, convenient synthesis and stable metabolism, which activate interferon gene stimulating protein and induce the production of type I interferon IFN- β.

Disclosure of Invention

The invention aims to provide a compound shown in a formula I, a preparation method thereof and application thereof in the aspect of tumor resistance.

In a first aspect of the invention, there is provided a compound of formula I, or an isomer, prodrug, solvate, hydrate or pharmaceutically acceptable salt thereof,

wherein,

R ¹ and R ² Independently selected from the group consisting of substituted or unsubstituted: H. halogen, amino, hydroxy, carboxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C3-C8 cycloalkoxy, 3-8 membered heterocycloalkyl containing 1-3 heteroatoms selected from N, O, S, 3-8 membered heterocycloalkoxy containing 1-3 heteroatoms selected from N, O, S, C6-C10 aryl, 3-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, S; or R ₁ And R ₂ Together with the carbon atom to which they are attached form a 5-14 membered heterocyclyl;

said R is ¹ And R ² The substituent(s) in (b) means being independently substituted with one or more substituents selected from the group consisting of: halogen, amino, hydroxy, carboxy, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C3-C8 cycloalkoxy, 3-8 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, S, C6-C10 aryl, 3-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, S;

X ¹ and X ² Independently selected from the group consisting of: H. d, halogen;

X ³ selected from the group consisting of: NH, O, S, se;

X ⁴ selected from the group consisting of: o, NR ⁵ 、S；

n is an integer selected from 0, 1,2, 3, 4, 5, 6, 7, 8;

R ³ independently selected from the group consisting of substituted or unsubstituted: H. carboxyl, sulfonic acid group, phosphoryl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, 3-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, S, 3-8 membered heterocycloalkyl containing 1-3 heteroatoms selected from N, O, S;

R ⁴ and R ⁵ Independently selected from the group consisting of substituted or unsubstituted: H. carboxyl, sulfonic acid group, phosphoryl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, 3-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, S, 3-8 membered heterocycloalkyl containing 1-3 heteroatoms selected from N, O, S;

the R is ³ 、R ⁴ And R ⁵ The substituent (b) means independently substituted with one or more substituents selected from the group consisting of: hydroxy, halogen, carboxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C12 alkoxy, C3-C8 cycloalkyl, C3-C8 cycloalkoxy, C6-C10 aryl, halogenated C6-C10 aryl, 3-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, S.

In another preferred embodiment, the "5-14 membered heterocyclyl" is a heterocyclyl containing at least 2O.

In another preferred embodiment, the "5-14 membered heterocyclyl" is a heterocyclyl containing 2O's.

In another preferred embodiment, the "5-14 membered heterocyclyl" is cycloalkoxy.

In another preferred embodiment, X ¹ And X ² Independently selected from the group consisting of: H. d, fluorine;

X ³ selected from the group consisting of: o and S;

n is an integer selected from 1,2, 3;

R ¹ and R ² Independently selected from the group consisting of substituted or unsubstituted: H. halogen, C2-C6 alkenyl, C1-C6 alkoxy, C3-C8 cycloalkoxy, 3-8 membered heterocycloalkoxy containing 1-3 heteroatoms selected from N, O, S; or R ¹ And R ² Together with the carbon atom to which they are attached form a 5-14 membered heterocycloalkoxy;

the R is ¹ And R ² The substituent (b) means independently substituted with one or more substituents selected from the group consisting of: halogen, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C3-C8 cycloalkoxy, 3-8 membered heterocyclyl containing 1-3 heteroatoms selected from N, O, S.

In another preferred embodiment, X ⁴ Selected from the group consisting of: o, NR ⁵ ；

n is an integer selected from 1,2, 3;

R ³ independently selected from the group consisting of substituted or unsubstituted: H. C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, 3-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, S, 3-8 membered heterocycloalkyl containing 1-3 heteroatoms selected from N, O, S;

the R is ³ 、R ⁴ And R ⁵ The substituent (b) means independently substituted with one or more substituents selected from the group consisting of: hydroxyl, halogen, carboxyl,C1-C6 alkyl, C3-C8 cycloalkyl, C1-C12 alkoxy, C3-C8 cycloalkoxy, C2-C6 alkenyl, C6-C10 aryl, halogenated C6-C10 aryl, 3-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, S.

In another preferred embodiment, X ⁴ Is O.

In another preferred embodiment, the compound is selected from the compounds listed in table 1.

In a second aspect of the present invention, there is provided a process for preparing a compound of the first aspect of the present invention, or an isomer, prodrug, solvate, hydrate or pharmaceutically acceptable salt thereof, selected from the group consisting of:

the method one comprises the following steps:

a-1) reacting a compound of formula 1 with a compound of formula 2 or a hydrochloride thereof in the presence of a condensing agent to obtain a compound of formula 3;

a-2) optionally reacting the compound of formula 3 with lawson's reagent to give the compound of formula 4;

wherein R is ¹ 、R ² 、R ³ 、R ⁴ 、X ¹ 、X ² 、X ⁴ N is as defined in the first aspect of the invention;

the second method comprises the following steps:

b-1) reacting the compound of formula 5 with the compound of formula 6 or a hydrochloride thereof in the presence of a condensing agent to obtain a compound of formula 7;

b-2) optionally subjecting the compound of formula 7 to a coupling reaction to obtain a compound of formula 8;

wherein R is ¹ 、R ² 、R ³ 、R ⁴ 、X ¹ 、X ² 、X ³ 、X ⁴ N is as defined in the first aspect of the invention, and R ² Is not a halogen.

In another preferred embodiment, the condensing agent is selected from the group consisting of: EDCI, HBTU, TBTU, HATU.

In another preferred embodiment, the Lawson's reagent is 2, 4-bis (p-methoxyphenyl) -1, 3-dithiodiphosphetane-2, 4 sulfide.

In a third aspect of the present invention, there is provided a pharmaceutical composition comprising:

(i) One or more therapeutically effective amounts of a compound of the first aspect of the invention, or its isomer, prodrug, solvate, hydrate or pharmaceutically acceptable salt thereof; and

(ii) A pharmaceutically acceptable carrier.

In another preferred embodiment, the pharmaceutical composition is an injection, a sachet, a tablet, a pill, a powder or a granule.

In another preferred embodiment, the pharmaceutical composition further comprises one or more second therapeutic agents, which are drugs for preventing and/or treating cancer.

In another preferred embodiment, the second therapeutic agent is a traditional cytotoxic chemotherapy drug or other anti-tumor immune drug.

In a fourth aspect of the present invention, there is provided a use of the compound of the first aspect of the present invention, or its isomer, prodrug, solvate, hydrate or pharmaceutically acceptable salt thereof, or the pharmaceutical composition of the third aspect of the present invention for the preparation of a formulation for the prevention and/or treatment of a disease associated with type I interferon.

In another preferred embodiment, the type I interferon is selected from the group consisting of: IFN-alpha, IFN-beta.

In another preferred embodiment, the type I interferon related diseases are selected from the group consisting of: breast cancer, ovarian cancer, liver cancer, melanoma, prostate cancer, colon cancer, and gastric cancer.

In a fifth aspect of the present invention, there is provided an interferon gene stimulating protein agonist comprising one or more compounds according to the first aspect of the present invention, or an isomer, prodrug, solvate, hydrate or pharmaceutically acceptable salt thereof.

In a sixth aspect of the present invention, there is provided a method for preventing and/or treating a disease associated with type I interferon, comprising the steps of: administering to a patient in need thereof a therapeutically effective amount of one or more compounds of the first aspect of the invention, or isomers, prodrugs, solvates, hydrates, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition of the third aspect of the invention.

In another preferred embodiment, the method is non-diagnostic, non-therapeutic.

It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments. Not to be repeated herein, depending on the space.

Detailed Description

The inventor unexpectedly prepares a compound shown in formula I with simple structure, convenient synthesis and stable metabolism through long-term and deep research, and the compound has excellent activation performance on interferon gene stimulating protein, thereby activating T cells and remarkably promoting the expression of interferon factor IFN-beta, and further realizing the effective treatment on tumors and complications thereof. On this basis, the inventors have completed the present invention.

Term(s) for

In the present invention, unless otherwise specified, the terms used have the ordinary meanings well known to those skilled in the art.

In the present invention, the term "halogen" means F, cl, br or I.

In the present invention, "C1-C6 alkyl" means a straight or branched alkyl group including 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, tert-pentyl, hexyl or the like.

In the present invention, the term "C3-C8 cycloalkyl" refers to a cyclic alkyl group having 3 to 8 carbon atoms in the ring, including, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.

In the present invention, the term "aromatic ring" or "aryl" has the same meaning, preferably "C6-C10 aryl". The term "C6-C10 aryl" refers to an aromatic ring group having 6 to 10 carbon atoms, such as phenyl, naphthyl, and the like, which does not contain heteroatoms in the ring.

In the present invention, the term "heterocycloaryl" or "heteroaryl" has the same meaning and refers to a heteroaromatic group containing one to more heteroatoms. For example, "C3-C10 heteroaryl" refers to an aromatic heterocycle containing 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, and 3 to 10 carbon atoms. Non-limiting examples include: furyl, thienyl, pyridyl, pyrazolyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, and the like. The heteroaryl ring may be fused to an aryl, heterocyclyl, or cycloalkyl ring, wherein the ring that is attached to the parent structure is a heteroaryl ring. Heteroaryl groups may be optionally substituted or unsubstituted.

In the present invention, the term "halo" means substituted by halogen.

In the present invention, the term "C2-C6 alkenyl group" means a straight or branched alkenyl group having 2 to 6 carbon atoms and containing one double bond, including, but not limited to, ethenyl, propenyl, butenyl, isobutenyl, pentenyl, hexenyl and the like.

In the present invention, the term "C2-C6 alkynyl" refers to a straight or branched alkynyl group having 2 to 6 carbon atoms and containing one triple bond, and includes, but is not limited to, ethynyl, propynyl, butynyl, isobutynyl, pentynyl, hexynyl, and the like.

In the present invention, the term "C1-C6 alkoxy group" means a straight or branched chain alkoxy group having 1 to 6 carbon atoms, including, but not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy and the like. C1-C4 alkoxy is preferred.

In the present invention, the term "substituted" means that one or more hydrogen atoms on a specified group are replaced with a specified substituent. Particular substituents are those described correspondingly in the foregoing, or as appearing in the examples. Unless otherwise specified, a certain substituted group may have one substituent selected from a specific group at any substitutable site of the group, and the substituents may be the same or different at each position. It will be understood by those skilled in the art that the combinations of substituents contemplated by the present invention are those that are stable or chemically achievable. Such substituents are for example (but not limited to): halogen, hydroxy (-COOH), carboxy (-COOH), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3-to 12-membered heterocyclyl (-COOH) aryl, heteroaryl, C1-C8 aldehyde, C2-C10 acyl, C2-C10 ester, amino, C1-C6 alkoxy, C1-C10 sulfonyl, and the like.

In the present invention, the term "sulfonic acid group" has the following structure:

in the present invention, the term "phosphoryl" has the following structure:

compound (I)

The invention provides a compound shown in formula I, or an isomer, a prodrug, a solvate, a hydrate or a pharmaceutically acceptable salt thereof,

wherein R is ¹ 、R ² 、R ³ 、R ⁴ 、X ¹ 、X ² 、X ³ 、X ⁴ N is as defined above.

In another preferred embodiment, in the compound, R ¹ 、R ² 、R ³ 、R ⁴ 、R ⁵ 、X ¹ 、X ² 、X ³ 、X ⁴ And n are respectively the corresponding groups in the specific compounds in the table 1.

In another preferred embodiment, the compound is preferably the compound prepared in the examples.

TABLE 1

Salt form

As used herein, the term "pharmaceutically acceptable salt" refers to a salt formed by a compound of the present invention and an acid or base, which is suitable for use as a pharmaceutical. Pharmaceutically acceptable salts include inorganic and organic salts. One preferred class of salts is that formed with acids from the compounds of the present invention. Suitable acids for forming salts include, but are not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid, and the like; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid and the like; and amino acids such as proline, phenylalanine, aspartic acid, glutamic acid, etc.

Another preferred class of salts are those of the compounds of the invention with bases, for example alkali metal salts (e.g. sodium or potassium), alkaline earth metal salts (e.g. magnesium or calcium), ammonium salts (e.g. lower alkanolammonium salts and other pharmaceutically acceptable amine salts), for example methylamine salts, ethylamine salts, propylamine salts, dimethylamine salts, trimethylamine salts, diethylamine salts, triethylamine salts, tert-butylamine salts, ethylenediamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, triethanolamine salts, and amine salts formed from morpholine, piperazine, lysine, respectively.

The term "solvate" refers to a complex of a compound of the present invention coordinated to solvent molecules in a specific ratio. "hydrate" refers to a complex formed by the coordination of a compound of the present invention with water.

The term "prodrug" includes a class of compounds which are biologically active or inactive in nature and which, when administered by an appropriate method, undergo a metabolic or chemical reaction in the body to convert the compound to formula I, or a salt or solution of a compound of formula I. The prodrugs include, but are not limited to, carboxylate, carbonate, phosphate, nitrate, sulfate, sulfone, sulfoxide, amide, carbamate, azo, phosphoramide, glucoside, ether, acetal forms of the compounds.

Preparation method

The process for the preparation of the compounds of formula I according to the invention is described in more detail below, but these particular processes do not limit the invention in any way. The compounds of the present invention may also be conveniently prepared by optionally combining various synthetic methods described in the present specification or known in the art, and such combinations may be readily carried out by those skilled in the art to which the present invention pertains.

Typically, the process for the preparation of the compounds of the present invention is as follows, wherein the starting materials and reagents used are commercially available without specific reference.

Typically, the compound is prepared by a method selected from the group consisting of:

the method comprises the following steps:

hydrolyzing the compound A under alkaline condition to obtain B, B and N, O-dimethylhydroxylamine hydrochlorideReacting under the condition of a mixture to obtain C; reacting C with methyl Grignard reagent to obtain D, further brominating to obtain E, reacting E with diethyl ester under alkaline condition to obtain F, further hydrolyzing and decarboxylating to obtain G, condensing G with substituted hydroxylamine or hydrazine to obtain H, and further reacting with Lawson reagent to obtain I. Wherein R is ¹ 、R ² 、R ³ 、R ⁴ 、R ⁵ 、X ¹ 、X ² 、X ⁴ N is as defined above;

the second method comprises the following steps:

and (3) obtaining J by the compound C under the condition of a halogenating reagent, further reacting with a Grignard reagent to obtain K, and further brominating to obtain L. L reacts with diethyl ester to obtain M, further decarboxylation is carried out to obtain N, N is condensed with substituted hydroxylamine or hydrazine to obtain O, and further coupling reaction is carried out to obtain P. Wherein R is ¹ 、R ² 、R ³ 、R ⁴ 、R ⁵ 、X ¹ 、X ² 、X ³ 、X ⁴ N is as defined above;

the third method comprises the following steps:

demethylating the compound F to obtain Q, further cyclizing to obtain R, and further decarboxylating to obtain S; condensing S and substituted hydroxylamine or hydrazine to obtain T; wherein R is ¹ 、R ² 、R ³ 、R ⁴ 、R ⁵ 、X ¹ 、X ² 、X ³ 、X ⁴ N is as defined above.

Pharmaceutical compositions and methods of administration

The present invention also provides a pharmaceutical composition comprising:

(i) One or more therapeutically effective amounts of said compound, or its isomer, prodrug, solvate, hydrate or pharmaceutically acceptable salt thereof; and

(ii) A pharmaceutically acceptable carrier.

The compound of the present invention and various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates thereof, and pharmaceutical compositions containing the compound as a main active ingredient can be used for treating, preventing and relieving diseases related to tumors because the compound of the present invention has excellent antitumor activity.

The pharmaceutical composition of the present invention comprises the compound of the present invention or a pharmacologically acceptable salt thereof in a safe and effective amount range and a pharmacologically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. The therapeutically effective amount is determined according to the age, condition, course of treatment, etc. of the subject to be treated. Typically, the pharmaceutical composition contains 1-2000mg of a compound of the invention per dose, more preferably, 10-1000mg of a compound of the invention per dose. Preferably, said "dose" is a capsule or tablet.

The "pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances which are suitable for human use and must be of sufficient purity and sufficiently low toxicity. By "compatible" is meant herein that the components of the composition are capable of intermixing with and with the compounds of the present invention without significantly diminishing the efficacy of the compounds. Examples of pharmaceutically acceptable carrier moieties are sugars (e.g., glucose, sucrose, lactose, etc.), starches (e.g., corn starch, potato starch, etc.), celluloses and derivatives thereof (e.g., sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g., propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (e.g., tween), wetting agents (e.g., sodium lauryl sulfate), colorants, flavors, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.

The mode of administration of the compounds or pharmaceutical compositions of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) Fillers or extenders, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) Binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, for example, glycerol; (d) Disintegrating agents, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents, such as paraffin; (f) absorption accelerators, e.g., quaternary amine compounds; (g) Wetting agents, such as cetyl alcohol and glycerol monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents.

Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shells such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active compound or compounds in such compositions may be delayed in release in a certain part of the digestive tract. Examples of embedding components which can be used are polymeric substances and wax-like substances. If desired, the active compound may also be in microencapsulated form with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly employed in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide and oils, especially cottonseed, groundnut, corn germ, olive, castor and sesame oils or mixtures of such materials and the like.

In addition to these inert diluents, the compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.

Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols and suitable mixtures thereof.

Dosage forms for topical administration of the compounds of the present invention include ointments, powders, patches, sprays, and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants which may be required if necessary.

The benzothiophene derivative represented by the general formula I and pharmaceutically acceptable salts thereof in the present invention can be administered alone or in combination with other pharmaceutically acceptable therapeutic agents, particularly in combination with conventional cytotoxic chemotherapy drugs and tumor immune checkpoint inhibitors. The pharmaceutically acceptable therapeutic agents include, but are not limited to, other acceptable therapeutic agents administered in combination with the benzothiophene derivatives represented by formula I, for example, monoclonal antibody drugs Opdivo and Keytruda, which act directly on the PD-1 protein on the surface of T cells to interrupt the binding of PD-1/PD-L1 to each other; and conventional cytotoxic chemotherapy small molecule drugs, such as antitumor drugs Methotrexate (MTX), 5-fluorouracil (5 FU) and the like which affect nucleic acid synthesis, antitumor drugs which affect nucleic acid transcription, such as doxorubicin, epirubicin, aclacinomycin, mithramycin and the like, antitumor drugs which act on tubulin synthesis, such as paclitaxel, vinorelbine and the like, aromatase inhibitors, such as aminoglutethimide and the like, cell signaling pathway inhibitors, such as epidermal growth factor receptor inhibitor Imatinib (Imatinib), gefitinib (Gefitinib), erlotinib (Erlotinib), lapatinib (Lapatinib) and the like. The components of the combination may be administered simultaneously or sequentially, in a single formulation or in different formulations. The combinations include not only combinations of a compound of the invention and one other active agent, but also combinations of a compound of the invention and two or more other active agents.

The treatment methods of the present invention can be administered alone or in combination with other therapeutic means or agents.

In the case of pharmaceutical compositions, a safe and effective amount of a compound of the present invention is administered to a mammal (e.g., a human) in need of treatment, wherein the administration is a pharmaceutically acceptable and effective dose, and the daily dose for a human of 60kg body weight is usually 1 to 2000mg, preferably 50 to 1000mg. Of course, the particular dosage will also take into account such factors as the route of administration, the health of the patient, and the like, which are within the skill of the skilled practitioner.

Compared with the prior art, the invention has the following main advantages:

(1) The compound has the characteristics of simple structure, easy synthesis and various administration modes;

(2) The compound has excellent activation performance on interferon gene stimulating protein, so that T cells are activated, the expression of an interferon factor IFN-beta is remarkably promoted, and the effective treatment on tumors and complications thereof is realized;

(3) The agonistic activity of the compound on interferon gene stimulating protein is obviously superior to that of TW201817723A public compound 1g.

The present invention is further illustrated below with reference to specific examples, which are not intended to limit the scope of the invention.

For the following examples, standard procedures and purification methods known to those skilled in the art can be used. Unless otherwise specified, starting materials are generally available from commercial sources, such as Aldrich Chemicals Co. And Acros Organics. Commercial solvents and reagents were generally used without further purification, and anhydrous solvents were passed through standard protocolsThe other reagents are commercially available analytical pure. Unless otherwise indicated, all temperatures are expressed in degrees Celsius (C.) and room or ambient temperature means 20 to 25 ℃. The structure of the compound is determined by nuclear magnetic resonance spectroscopy (NMR). The nuclear magnetic resonance hydrogen spectral shift (δ) is given in parts per million (ppm). Hydrogen nuclear magnetic resonance spectroscopy was performed using a Mercury-300MHz nuclear magnetic resonance spectrometer and deuterated chloroform (CDCl) ₃ ) Deuterated methanol (CD) ₃ OD) as solvent and Tetramethylsilane (TMS) as internal standard.

The chromatographic column generally uses 200-300 mesh silica gel as a carrier.

In the above discussion and in the examples below, the following abbreviations have the following meanings. An abbreviation has a generally accepted meaning if it is not defined.

RT is room temperature;

DIPEA is N, N-diisopropylethylamine;

THF is tetrahydrofuran.

TBTU is O-benzotriazole-N, N, N ', N' -tetramethylurea tetrafluoroborate;

selectfluor is 1-chloromethyl-4-fluoro-1, 4-diazotized bicyclo 2.2.2 octane bis (tetrafluoroborate) salt.

1. Examples of preparation of Compounds

The following preparations exemplarily prepare a part of the compounds of formula I of the present invention, each of which is represented by S1 to S33, respectively.

1. Synthesis of Compound S1

Step 1: compound 1a (1 eq) was dissolved in anhydrous methanol/tetrahydrofuran (1), followed by addition of an aqueous solution of KOH (10 eq) and heating to 60 ℃ for 1 hour. Most of the organic solvent is spun off, then the pH value is adjusted to 5-6 by 1N HCl, and the compound 1b is obtained after filtration and drying. ¹ H NMR(400MHz,DMSO)δ13.17(s,1H),7.94(s,1H),7.58(s,1H),7.48(s,1H),3.85(s,3H),3.82(s,3H)。

Step 2: the compound 1b (1 eq) was suspended in dichloromethane, and then N, O-dimethylhydroxylamine hydrochloride (1.1 eq), EDCI (1.5 eq), and triethylamine (2.5 eq) were added in this order to react at room temperature for 18 hours. After quenching the reaction with saturated aqueous sodium bicarbonate, extraction with ethyl acetate was performed, and then the organic phase was concentrated and separated by column chromatography to obtain compound 1c. ¹ H NMR(400MHz,CDCl ₃ )δ8.09(s,1H),7.25(s,1H),7.24(s,1H),3.96(s,3H),3.95(s,3H),3.81(s,3H),3.40(s,3H)。

And 3, step 3: compound 1c (1 eq) was dissolved in tetrahydrofuran, and methylmagnesium bromide (1.0M in THF,3 eq) was added slowly at-10 ℃ and then allowed to warm to room temperature for 3 hours. Quenching with 1N HCl, extracting with ethyl acetate, and separating by column chromatography to obtain compound 1d. ¹ H NMR(400MHz,CDCl ₃ )δ7.83(s,1H),7.26(s,1H),7.25(s,1H),3.98(s,3H),3.96(s,3H),2.63(s,3H)。

And 4, step 4: compound 1d (1 eq) was dissolved in chloroform, pyridine tribromide (1.1 eq) was added in two portions at 0 ℃ and then allowed to cool to room temperature for reaction overnight. After the reaction was complete, the solvent was spin dried, the resulting solid was stirred in water for about 10 minutes, filtered, and the resulting solid was recrystallized from ethyl acetate to give compound 1e. ¹ H NMR(400MHz,DMSO)δ8.29(s,1H),7.63(s,1H),7.48(s,1H),4.87(s,2H),3.87(s,3H),3.85(s,3H)。

And 5: potassium carbonate (0.65 eq) was suspended in DMF and diethyl malonate (1.05) was added at room temperatureeq), after stirring for 3 hours, compound 1e (1 eq) is added and the temperature is raised to 110 ℃ for 4 hours. After the reaction is finished, cooling the reaction liquid to room temperature, quenching the reaction liquid by using water, then extracting the reaction liquid by using ethyl acetate, and separating the reaction liquid by using column chromatography to obtain a compound 1f. ¹ H NMR(400MHz,CDCl ₃ )δ7.92(s,1H),7.25(s,1H),7.24(s,1H),4.30–4.19(m,4H),4.07(t,1H,J＝7.2Hz),3.98(s,3H),3.95(s,3H),3.63(d,2H,J＝7.2Hz),1.29(t,6H,J＝7.1Hz)。

Step 6: compound 1f was dissolved in 1, 4-dioxane, followed by the addition of an appropriate amount of 6N hydrochloric acid and refluxing overnight. After the reaction is finished, cooling the reaction liquid to room temperature, spin-drying the solvent, and recrystallizing with ethanol to obtain 1g of the compound. ¹ H NMR(400MHz,DMSO)δ12.19(s,1H),8.20(s,1H),7.60(s,1H),7.48(s,1H),3.86(s,3H),3.84(s,3H),3.26(t,2H,J＝6.4Hz),2.60(t,2H,J＝6.3Hz).

And 7: the compound (1 g, 1 eq) was dissolved in N, N-dimethylformamide, and then hydroxylamine hydrochloride (1.5 eq), condensing agent TBTU (3 eq), N, N-diisopropylethylamine (5 eq) were added in this order to react at room temperature overnight. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound S1. ¹ H NMR(400MHz,CDCl ₃ +CD ₃ OD)δ7.41(s,1H),7.22(s,1H),7.20(s,1H),3.94(s,3H),3.93(s,3H),3.11(t,2H,J＝8.0Hz),2.68(t,2H,J＝8.0Hz)；MS(EI):309.

2. Synthesis of Compound S2

1g (1 eq) of the compound was dissolved in N, N-dimethylformamide, followed by the sequential addition of hydrazine hydrochloride (1.0 eq), TBTU (3 eq), N, N-diisoPropylethylamine (5 eq) was reacted at room temperature overnight. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column chromatography to obtain compound S2. ¹ H NMR(400MHz,DMSO)δ9.87(s,1H),8.19(s,1H),7.59(s,1H),7.48(s,1H),3.86(s,3H),3.83(s,3H),3.27(t,2H,J＝8.0Hz),2.54(t,2H,J＝8.0Hz)；MS(EI):308.

3. Synthesis of Compound S3

Compound 1g (1 eq) was dissolved in N, N-dimethylformamide, followed by the sequential addition of N-methylhydrazine hydrochloride (1.0 eq), TBTU (3 eq), N-diisopropylethylamine (5 eq) and reaction at room temperature overnight. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound S3. ¹ H NMR(400MHz,DMSO)δ9.80(s,1H),8.11(s,1H),7.53(s,1H),7.41(s,1H),3.90(s,3H),3.87(s,3H),3.22(t,2H,J＝8.0Hz),3.04(s,3H),2.50(t,2H,J＝8.0Hz)；MS(EI):322.

4. Synthesis of Compound S4

1g (1 eq) of the compound was dissolved in N, N-dimethylformamide, and then N-methylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), N, N-diisopropylethylamine (5 eq) were added in this order and reacted at room temperature overnight. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column chromatography to obtain compound S4. ¹ H NMR(400MHz,DMSO)δ7.99(s,1H),7.29(s,1H),7.28(s,1H),3.99(s,3H),3.96(s,3H),3.35(t,2H,J＝8.0Hz),3.25(s,3H),2.93(t,2H,J＝8.0Hz)；MS(EI):323.

5. Synthesis of Compound S5

The compound (1 g, 1 eq) was dissolved in N, N-dimethylformamide, and then N-difluoromethylhydroxylamine (1.0 eq), a condensing agent TBTU (3 eq), and N, N-diisopropylethylamine (5 eq) were added in this order to react at room temperature overnight. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound S5. ¹ H NMR(400MHz,CDCl ₃ )δ7.94(s,1H),7.25(s,1H),7.24(s,1H),7.20(m,1H),3.95(s,3H),3.93(s,3H),3.38(t,2H,J＝8.0Hz),2.97(t,2H,J＝8.0Hz)；MS(EI):359.

6. Synthesis of Compound S6

1g (1 eq) of the compound was dissolved in N, N-dimethylformamide, and then N-ethylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), and N, N-diisopropylethylamine (5 eq) were added in this order to react at room temperature overnight. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column chromatography to obtain compound S6. ¹ H NMR(400MHz,CDCl ₃ )δ8.21(brs,1H),7.94(s,1H),7.27(s,1H),7.25(s,1H),3.99(s,3H),3.96(s,3H),3.84–3.68(m,2H),3.53–3.40(m,2H),2.98–2.70(m,2H),1.20-1.37(m,3H)；MS(EI):337。

7. Synthesis of Compound S7

1g (1 eq) of the compound was dissolved in N, N-dimethylformamide, and then N-propylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), and N, N-diisopropylethylamine (5 eq) were added in this order to react at room temperature overnight. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound S7. ¹ H NMR(400MHz,CDCl ₃ )δ8.19(brs,1H),7.91(s,1H),7.24(s,1H),7.20(s,1H),3.94(s,3H),3.90(s,3H),3.81–3.76(m,2H),3.49–3.45(m,2H),2.92–2.74(m,2H),1.35-1.29(m,2H),1.19(t,3H,J＝8.0Hz)；MS(EI):351.10。

8. Synthesis of Compound S8

1g (1 eq) of the compound was dissolved in N, N-dimethylformamide, and then N-allylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), and N, N-diisopropylethylamine (5 eq) were added in this order to react at room temperature overnight. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound S8. ¹ H NMR(400MHz,CDCl ₃ )δ8.23(brs,1H),8.01(s,1H),7.31(s,1H),7.23(s,1H),5.78(m,1H),5.23(m,2H),3.93(s,3H),3.89(s,3H),3.72(d,2H,J＝6.2Hz),3.42(m,2H),2.48(m,2H)；MS(EI):349.0。

9. Synthesis of Compound S9

Compound S8 (1 eq) was dissolved in 1, 4-dioxane and then dihydroxylation mixture reagent AD-Mix-. Beta. (1.5 eq) was added and allowed to react overnight at room temperature. After the reaction, the reaction solution was poured into ice water, extracted with dichloromethane, and the organic phase was collected and purified by column to obtain compound S9. ¹ H NMR(400MHz,CD ₃ OD)δ8.31(brs,1H),8.04(s,1H),7.39(s,1H),7.25(s,1H),4.11(m,1H),3.95(s,3H),3.92(s,3H),3.86(m,2H),3.67(m,2H),3.54(m,2H),2.46(m,2H)；MS(EI):383。

10. Synthesis of Compound S10

1g (1 eq) of the compound was dissolved in N, N-dimethylformamide, and then N-isopropylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), and N, N-diisopropylethylamine (5 eq) were added in this order to react at room temperature overnight. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound S10. ¹ H NMR(400MHz,CDCl ₃ )δ7.89(s,1H),7.30(brs,1H),7.25(s,1H),7.23(s,1H),3.98(s,3H),3.96(s,3H),3.37(t,2H,J＝6.8Hz),3.26(m,1H),2.83(t,2H,J＝6.8Hz,),1.11(d,6H,J＝4.0Hz)；MS(EI):351.

11. Synthesis of Compound S11

1g (1 eq) of the compound was dissolved in N, N-dimethylformamide, and then N-cyclopropylhydroxylamine (1.0 eq), a condensing agent TBTU (3 eq), N, N-diisopropylethylamine (5 eq) were added in this order and reacted at room temperature overnight. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound S11. ¹ H NMR(400MHz,CDCl ₃ )δ7.97(s,1H),7.27(s,1H),7.26(s,1H),3.97(s,3H),3.94(s,3H),3.34(t,2H,J＝8.0Hz),3.28(m,1H),2.97(t,2H,J＝8.0Hz),0.94(m,4H).MS(EI):349.

12. Synthesis of Compound S12

1g (1 eq) of the compound was dissolved in N, N-dimethylformamide, and then N-cyclohexylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), and N, N-diisopropylethylamine (5 eq) were added in this order to react at room temperature overnight. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column chromatography to obtain compound S12. ¹ H NMR(400MHz,CDCl ₃ )δ7.89(s,1H),7.40(brs,1H),7.26(s,1H),7.25(s,1H),3.98(s,3H),3.96(s,3H),3.36(t,J＝6.8Hz,2H),2.92(m,1H),2.82(t,J＝6.8Hz,2H),1.87(d,J＝12.2Hz,2H),1.75(d,J＝12.6Hz,2H),1.20(m,6H).MS(EI):391.

13. Synthesis of Compound S13

Mixing compound 1g (1)eq) was dissolved in N, N-dimethylformamide, followed by the addition of N-benzylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), and N, N-diisopropylethylamine (5 eq) in that order, and the reaction was allowed to proceed overnight at room temperature. After the reaction, the reaction mixture was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column chromatography to obtain compound S13. ¹ H NMR(400MHz,CDCl ₃ )δ7.85(s,1H),7.70(brs,1H),7.39-7.30(m,5H),7.25(s,1H),7.24(s,1H),4.16(s,2H),3.98(s,3H),3.96(s,3H),3.30(t,2H,J＝6.8Hz,),2.77(t,2H,J＝6.8Hz),MS(EI):399.

14. Synthesis of Compound S14

1g (1 eq) of the compound was dissolved in N, N-dimethylformamide, and then N-difluorobenzylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), N, N-diisopropylethylamine (5 eq) were added in this order and reacted at room temperature overnight. After the reaction, the reaction mixture was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column chromatography to obtain compound S14. ¹ H NMR(400MHz,CDCl ₃ )δ7.94(s,1H),7.80(brs,1H),7.52-7.49(m,5H),7.34(s,1H),7.27(s,1H),3.96(s,3H),3.94(s,3H),3.30(t,2H,J＝6.8Hz,),2.77(t,2H,J＝6.8Hz),MS(EI):435.

15. Synthesis of Compound S15

The compound (1 g, 1 eq) was dissolved in N, N-dimethylformamide, and then fluorobenzylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), and N, N-diisopropylethylamine (5 eq) were added in this order to react at room temperature overnight. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound S15. ¹ H NMR(400MHz,CDCl ₃ )δ7.73(s,1H),7.78(brs,1H),7.34(s,1H),7.27(s,1H),6.97(m,1H),9.89(m,1H),3.92(s,3H),3.89(s,3H),3.37(t,2H,J＝6.8Hz,),2.89(t,2H,J＝6.8Hz),MS(EI):453.

16. Synthesis of Compound S16

Compound 1g (1 eq) was dissolved in N, N-dimethylformamide, followed by the sequential addition of pyridine methylene hydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), N-diisopropylethylamine (5 eq) and allowed to react overnight at room temperature. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound S16. ¹ H NMR(400MHz,CDCl ₃ )δ8.48(s,1H),8.14(d,1H,J＝7.5Hz),7.80(s,1H),7.76(d,1H,J＝7.5Hz),7.73(brs,1H),7.32(m,1H),7.28(s,1H),7.22(s,1H),4.23(s,2H),3.96(s,3H),3.94(s,3H),3.35(t,2H,J＝6.8Hz,),2.79(t,2H,J＝6.8Hz),MS(EI):400.

17. Synthesis of Compound S17

1g (1 eq) of the compound was dissolved in N, N-dimethylformamide, and then N-phenylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), and N, N-diisopropylethylamine (5 eq) were added in this order to react at room temperature overnight. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound S17. ¹ H NMR(400MHz,CDCl ₃ )δ8.05(s,1H),7.85(brs,1H),7.52-7.40(m,5H),7.28(s,1H),7.23(s,1H),3.96(s,3H),3.91(s,3H),3.20(t,2H,J＝6.8Hz,),2.67(t,2H,J＝6.8Hz).MS(EI):385.

18. Synthesis of Compound S18

The compound (1 g, 1 eq) was dissolved in N, N-dimethylformamide, and then hydroxylamine sulfonate (1.0 eq), condensing agent TBTU (3 eq), N, N-diisopropylethylamine (5 eq) were added in this order to react at room temperature overnight. After the reaction, the reaction mixture was poured into ice water, extracted with ethyl acetate and collectedThe organic phase was collected and purified by column to give compound S18. ¹ H NMR(400MHz,CDCl ₃ )δ ¹ H NMR(400MHz,CDCl ₃ +CD ₃ OD)δ12.04(brs,1H,),7.43(s,1H),7.29(s,1H),7.19(s,1H),3.96(s,3H),3.94(s,3H),3.10(t,2H,J＝8.0Hz),2.69(t,2H,J＝8.0Hz).MS(EI):389.

19. Synthesis of Compound S19

Compound 1g (1 eq) was dissolved in N, N-dimethylformamide, followed by sequential addition of methoxyhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), N-diisopropylethylamine (5 eq) and reaction at room temperature overnight. After the reaction, the reaction mixture was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column chromatography to obtain compound S19. ¹ H NMR(400MHz,CDCl ₃ )δ8.62(brs 1H),7.90(s,1H),7.24(s,2H),3.98(s,3H),3.95(s,3H),3.77(s,3H),3.40(t,J＝6.5Hz,2H),2.53(brs,2H)；MS(EI):323.0。

20. Synthesis of Compound S20

1g (1 eq) of the compound was dissolved in N, N-dimethylformamide, and then O-benzylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), and N, N-diisopropylethylamine (5 eq) were added in this order to react at room temperature overnight. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound S20. ¹ H NMR(400MHz,CDCl ₃ )δ8.39(s,1H),7.89(s,1H),7.40–7.36(m,5H),7.25(s,2H),4.91(s,2H),3.98(s,3H),3.96(s,3H),3.38(brs,2H),2.50(brs,2H)；MS(EI):399.0.

21. Synthesis of Compound S21

Will combine with1g (1 eq) of the compound was dissolved in N, N-dimethylformamide, and then N-methyl, O-methyl hydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), N, N-diisopropylethylamine (5 eq) were added in this order to react overnight at room temperature. After the reaction, the reaction mixture was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column chromatography to obtain compound S21. ¹ H NMR(400MHz,CDCl ₃ )δ7.92(s,1H),7.26(s,1H),7.25(s,1H),3.98(s,3H),3.95(s,3H),3.77(s,3H),3.35(t,2H,J＝8.0Hz),3.21(s,3H),2.92(t,2H,J＝8.0Hz).MS(EI):399.0.

22. Synthesis of Compound S22

Step 1: compound 1f (1 eq) was dissolved in dichloromethane, 1.0M boron tribromide in dichloromethane (6 eq) was slowly added dropwise at-78 ℃ and reacted at-78 ℃ for half an hour, followed by moving to room temperature for about half an hour. After the reaction is finished, water is slowly added dropwise under an ice bath to quench, and then dichloromethane is used for extraction, and the compound 22a is obtained through column purification. ¹ H NMR(400MHz,CDCl ₃ )δ7.93(s,1H),7.25(s,1H),7.18(s,1H),4.71(t,J＝7.3Hz,1H),4.10(dq,J＝13.3,6.8Hz,4H),3.11(qd,J＝17.3,7.0Hz,2H),1.29(t,J＝7.1Hz,6H)。

And 2, step: compound 22a (1 eq) was dissolved in N, N-dimethylformamide, and triethylene glycol di-p-toluenesulfonate (1 eq), potassium carbonate (4.5 eq) were added in that order, reacted at 90 ℃ overnight, cooled to room temperature, poured into ice water, extracted with ethyl acetate, and purified by column chromatography to give compound 22b. ¹ H NMR(400MHz,CDCl ₃ )δ8.03(s,1H),7.46(s,1H),7.35(s,1H),4.77(t,J＝7.3Hz,1H),4.23(dd,J＝8.3,4.3Hz,4H),4.16(d,J＝7.1Hz,2H),3.95–3.91(m,2H),3.90–3.86(m,2H),3.82(s,4H)，3.08(d,J＝7.2Hz,2H),1.22(t,J＝7.1Hz,6H)。

And step 3: compound 22b is dissolved in 1, 4-dioxane, followed by the addition of the appropriate amount of 6N hydrochloric acid and refluxing overnight. After the reaction is finished, cooling the reaction liquid to room temperature, spin-drying the solvent, and recrystallizing with ethanol to obtain the compound 22c. ¹ H NMR(500MHz,MeOD)δ7.83(s,1H),7.37(s,1H),7.28(s,1H),4.15(dd,J＝8.0,5.5Hz,4H),3.87–3.82(m,2H),3.81–3.78(m,2H),3.73(s,4H),3.23(t,J＝6.3Hz,2H),2.69(t,J＝6.4Hz,2H)。

And 4, step 4: compound 22c (1 eq) was dissolved in N, N-dimethylformamide, followed by the addition of N-isopropylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), N-diisopropylethylamine (5 eq) in that order, and allowed to react overnight at room temperature. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column chromatography to obtain compound S22. ¹ H NMR(400MHz,CDCl ₃ )δ7.89(s,1H),7.35(brs,1H),7.29(s,1H),7.24(s,1H),4.17(dd,J＝8.0,5.5Hz,4H),3.89–3.83(m,2H),3.85–3.80(m,2H),3.76(s,4H),3.35(t,2H,J＝6.8Hz),3.21(m,1H),2.79(t,2H,J＝6.8Hz,),1.13(d,6H,J＝4.0Hz).MS(EI):437.

23. Synthesis of Compound S23

Step 1: compound 1f (1 eq) was dissolved in dichloromethane; then, anhydrous aluminum chloride (5 eq) was added thereto, and the mixture was reacted at 45 ℃ for 8 hours, cooled to room temperature, quenched with an appropriate amount of 1N hydrochloric acid, extracted with dichloromethane, and purified by column chromatography to give compound 23a. ¹ H NMR(400MHz,CDCl ₃ )δ7.90(s,1H),7.32(s,1H),7.23(s,1H),6.09(s,1H),4.24(pd,J＝7.7,3.6Hz,4H),4.07(t,J＝7.2Hz,1H),3.98(s,3H),3.62(d,J＝7.2Hz,2H),1.29(t,J＝7.1Hz,6H)。

Step 2: compound 23a (1 eq) was dissolved in N, N-dimethylformamide, and N- (3-chloropropyl) morpholine (1 eq), potassium carbonate (3 eq) and 4-dimethylaminopyridine (0.01 eq) were added in that order, reacted at 80 ℃ for 3 hours, cooled to room temperature, poured into ice water, extracted with ethyl acetate and purified by column to give compound 23b. ¹ H NMR(400MHz,CDCl ₃ )δ7.91(s,1H),7.29(s,1H),7.24(s,1H),4.29–4.21(m,4H),4.18(t,J＝6.5Hz,2H),4.07(t,J＝7.2Hz,1H),3.93(s,3H),3.75-3.73(m,4H),3.62(d,J＝7.2Hz,2H),2.58-2.55(m,2H),2.58-2.47(m,4H),2.15–2.04(m,2H),1.29(t,J＝7.1Hz,6H)。

And 3, step 3: compound 23b was dissolved in 1, 4-dioxane, followed by addition of the appropriate amount of 6N hydrochloric acid and refluxing overnight. After the reaction is finished, cooling the reaction solution to room temperature, spin-drying the solvent, and recrystallizing with ethanol to obtain the compound 23c. ¹ H NMR(400MHz,DMSO)δ12.20(s,1H),8.21(s,1H),7.63(s,1H),7.51(s,1H),4.17(t,J＝5.7Hz,2H),3.99(d,J＝12.7Hz,2H),3.85(s,3H),3.75(t,J＝12.2Hz,2H),3.50(d,J＝12.0Hz,2H),3.29–3.23(m,4H),3.10(dd,J＝21.6,9.7Hz,2H),2.60(t,J＝6.2Hz,2H),2.28–2.20(m,2H)。

And 4, step 4: compound 23c (1 eq) was dissolved in N, N-dimethylformamide, followed by the sequential addition of N-isopropylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), and N, N-diisopropylethylamine (5 eq) and reacted at room temperature overnight. After the reaction, the reaction mixture was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column chromatography to obtain compound S23. ¹ H NMR(400MHz,CDCl ₃ )δ8.27(s,1H),7.66(s,1H),7.53(s,1H),4.14(t,J＝5.7Hz,2H),3.92(d,J＝12.7Hz,2H),3.89(s,3H),3.77(t,J＝12.2Hz,2H),3.56(d,J＝12.0Hz,2H),3.34–3.26(m,4H),3.19(m,1H),3.12(dd,J＝21.6,9.7Hz,2H),2.63(t,J＝6.2Hz,2H),2.26–2.18(m,2H),1.10(d,6H,J＝4.0Hz).MS(EI):464.

24. Synthesis of Compound S24

Step 1: compound 1f (1 eq) was dissolved in acetonitrile and the selective fluoro reagent was added at room temperature and allowed to react overnight. After the reaction is finished, the mixture is quenched by saturated sodium bicarbonate solution, extracted by ethyl acetate, collected and purified by a column to obtain the compound 24a. ¹ H NMR(400MHz,CDCl ₃ )δ8.03(s,1H),7.08(s,1H),4.25(ddq,J＝14.8,7.5,3.7Hz,4H),4.07(t,1H,J＝7.2Hz),3.99(s,3H),3.97(s,3H),3.64(d,2H,J＝7.2Hz),1.30(t,6H,J＝7.1Hz)。

And 2, step: compound 24a is dissolved in 1, 4-dioxane, followed by the addition of the appropriate amount of 6N hydrochloric acid and refluxing overnight. After the reaction is finished, cooling the reaction liquid to room temperature, spin-drying the solvent, and recrystallizing with ethanol to obtain a compound 24b. ¹ H NMR(400MHz,DMSO)δ12.19(s,1H),8.32(s,1H),7.58(s,1H),3.92(s,3H),3.86(s,3H),3.32(t,2H,J＝6.4Hz),2.59(t,2H,J＝6.3Hz)。

And step 3: the compound 24b (1 eq) was dissolved in N, N-dimethylformamide, and then hydroxylamine hydrochloride (1.0 eq), a condensing agent TBTU (3 eq), and N, N-diisopropylethylamine (5 eq) were added in this order to react at room temperature overnight. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound S24. ¹ H NMR(400MHz,DMSO)δ8.35(s,1H),7.56(s,1H),3.95(s,3H),3.89(s,3H),3.32(t,2H,J＝6.4Hz),2.61(t,2H,J＝6.3Hz).MS(EI):327.

25. Synthesis of Compound S25

Compound 24b (1 eq) was dissolved in N, N-dimethylformamide, followed by the sequential addition of N-isopropylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), N-diisopropylethylamine (5 eq) and allowed to react overnight at room temperature. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound S25. ¹ H NMR(400MHz,CDCl ₃ )δ8.37(s,1H),7.53(s,1H),3.94(s,3H),3.90(s,3H),3.32(t,2H,J＝6.4Hz),3.24(m,1H),2.61(t,2H,J＝6.3Hz),1.13(d,J＝4.0Hz,6H).MS(EI):369.

26. Synthesis of Compound S26

Compound 24b (1 eq) was dissolved in N, N-dimethylformamide, followed by the sequential addition of N-benzylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), and N, N-diisopropylethylamine (5 eq) and reacted at room temperature overnight. After the reaction, the reaction mixture was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column chromatography to obtain compound S26. ¹ H NMR(400MHz,CDCl ₃ )δ8.40(s,1H),7.57(s,1H),,7.40-7.35(m,5H),4.02(s,2H),3.99(s,3H),3.96(s,3H),3.24(t,2H,J＝6.8Hz,),2.2(t,2H,J＝6.8Hz).MS(EI):417.

27. Synthesis of Compound S27

Dissolving the compound S10 (1 eq) in toluene, adding Lawson reagent (1.5 eq), heating to 120 ℃, refluxing for about 10 minutes, cooling to room temperature, quenching with saturated sodium bicarbonate solution under ice bath, extracting with ethyl acetate, and separating and purifying by column to obtain the compound S27. ¹ H NMR(400MHz,CDCl ₃ )δ7.8(s,1H),7.23(s,1H),7.19(s,1H),3.99(s,3H),3.98(s,3H),3.34(t,2H,J＝6.8Hz),3.22(m,1H),2.87(t,2H,J＝6.8Hz,),1.10(d,6H,J＝4.0Hz)；MS(EI):367.

28. Synthesis of Compound S28

Step 1: dissolving 1eq of compound 28a (prepared according to the synthesis method of 1 c) in dichloromethane, adding NBS (1.1 eq), continuously stirring the reaction solution for 6 hours, removing the solvent after TLC detection reaction is finished, and purifying by column chromatography to obtain compound 28b;

step 2: compound 28b (1 eq) was dissolved in tetrahydrofuran, and methylmagnesium bromide (1.0M in THF,3 eq) was added slowly at-10 ℃ and allowed to react at room temperature for 3 hours. Quenching with 1N HCl, extracting with ethyl acetate, and separating by column chromatography to obtain compound 28c;

and step 3: compound 28c (1 eq) was dissolved in chloroform, pyridine tribromide (1.1 eq) was added in two portions at 0 ℃ and then allowed to warm to room temperature for reaction overnight. After the reaction was complete, the solvent was spin dried, the resulting solid was stirred in water for about 10 minutes, filtered, and the resulting solid was recrystallized from ethyl acetate to give compound 28d.

And 4, step 4: potassium carbonate (0.65 eq) was suspended in DMF, then diethyl malonate (1.05 eq) was added at room temperature, after stirring for 3 hours compound 28d (1 eq) was added, and the temperature was raised to 110 ℃ for 4 hours reaction. Reaction junctionAfter the reaction solution is cooled to room temperature, the reaction solution is quenched by water, and then extracted by ethyl acetate, and the compound 28e is obtained by column chromatography separation. ¹ H NMR(400MHz,CDCl ₃ )δ7.99(s,1H),7.30(s,1H),7.28(s,1H),4.32–4.20(m,4H),4.11(t,1H,J＝7.2Hz),3.97(s,3H)3.66(d,2H,J＝7.2Hz),1.32(t,6H,J＝7.1Hz)。

And 5: compound 28e was dissolved in 1, 4-dioxane, then the appropriate amount of 6N hydrochloric acid was added and refluxed overnight. After the reaction is finished, cooling the reaction liquid to room temperature, spin-drying the solvent, and recrystallizing with ethanol to obtain a compound 28f. ¹ H NMR(400MHz,DMSO)δ12.24(s,1H),8.34(s,1H),7.68(s,1H),7.50(s,1H),3.90(s,3H),3.32(t,2H,J＝6.4Hz),2.63(t,2H,J＝6.3Hz).

Step 6: compound 28f (1 eq) was dissolved in N, N-dimethylformamide, followed by the sequential addition of hydroxylamine hydrochloride (1.5 eq), condensing agent TBTU (3 eq), N-diisopropylethylamine (5 eq) and reaction at room temperature overnight. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column chromatography to obtain compound S28. ¹ H NMR(400MHz,CDCl ₃ +CD ₃ OD)δ7.50(s,1H),7.29(s,1H),7.22(s,1H),3.96(s,3H),3.28(m,1H),3.14(t,2H,J＝8.0Hz),2.71(t,2H,J＝8.0Hz)，1.14(d,6H,J＝4.0Hz)；MS(EI):399.

29. Synthesis of Compound S29

S28 (1 eq), alkenyl borate (1.1 eq) and Pd as a catalyst ₂ (dba) ₃ (0.05 eq), ligand X-Phos (0.05 eq) and Cs ₂ CO ₃ (1 eq) was dissolved in dry toluene and reacted at 110 ℃ for 12 hours,after TLC detection reaction, ethyl acetate is added for dilution, saturated saline is used for washing, and the organic phase is anhydrous Na ₂ SO ₄ Drying, concentrating under reduced pressure, and purifying by column to obtain compound S29. ¹ H NMR(400MHz,CDCl ₃ +CD ₃ OD)δ8.04(s,1H),7.65(s,1H),7.36(s,1H),6.45(m,1H),5.28-5.43(m,2H),3.94(s,3H),3.23(m,1H),3.17(t,2H,J＝8.0Hz),2.67(t,2H,J＝8.0Hz)，1.10(d,6H,J＝4.0Hz)；MS(EI):347.

30. Synthesis of Compound S30

Step 1: compound 22a (1 eq) was dissolved in N, N-dimethylformamide, dibromomethane (1 eq) and potassium carbonate (4.5 eq) were added in sequence, reacted at 90 ℃ overnight, cooled to room temperature, poured into ice water, extracted with ethyl acetate and purified by column to give compound 30a.

Step 2: compound 30a is dissolved in 1, 4-dioxane, followed by the addition of the appropriate amount of 6N hydrochloric acid and refluxing overnight. After the reaction is finished, cooling the reaction liquid to room temperature, spin-drying the solvent, and recrystallizing with ethanol to obtain a compound 30b.

And 3, step 3: compound 30b (1 eq) was dissolved in N, N-dimethylformamide, followed by the sequential addition of N-isopropylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), N-diisopropylethylamine (5 eq) and allowed to react overnight at room temperature. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column chromatography to obtain compound S30. ¹ H NMR(400MHz,CDCl ₃ )δ7.91(s,1H),7.43(brs,1H),7.30(s,1H),7.22(s,1H),6.01(s,2H),3.32(t,2H,J＝6.8Hz),3.21(m,1H),2.75(t,2H,J＝6.8Hz,),1.13(d,6H,J＝4.0Hz).MS(EI):335.

31. Synthesis of Compound S31

Step 1: compound 22a (1 eq) was dissolved in N, N-dimethylformamide, and 1, 2-dibromoethane (1 eq), potassium carbonate (4.5 eq) were added in that order, reacted at 90 ℃ overnight, cooled to room temperature, poured into ice water, extracted with ethyl acetate, and purified by column chromatography to give compound 31a.

Step 2: compound 31a was dissolved in 1, 4-dioxane, followed by addition of an appropriate amount of 6N hydrochloric acid and refluxing overnight. After the reaction is finished, cooling the reaction solution to room temperature, spin-drying the solvent, and recrystallizing with ethanol to obtain the compound 31b.

And step 3: the compound 31b (1 eq) was dissolved in N, N-dimethylformamide, followed by the addition of N-isopropylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), and N, N-diisopropylethylamine (5 eq) in this order, and reacted at room temperature overnight. After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column to obtain compound S31. ¹ H NMR(400MHz,CDCl ₃ )δ7.90(s,1H),7.32(s,1H),7.23(s,1H),4.21(s,4H),3.34(t,2H,J＝6.8Hz),3.22(m,1H),2.72(t,2H,J＝6.8Hz,),1.10(d,6H,J＝4.0Hz).MS(EI):349.

32. Synthesis of Compound S32

1g (1 eq) of the compound was dissolved in N, N-dimethylformamide, followed by the sequential addition of N-methyl acetateHydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), N, N-diisopropylethylamine (5 eq) were reacted at room temperature overnight. After the reaction is finished, pouring the reaction solution into ice water, extracting with ethyl acetate, collecting an organic phase, and purifying by a column to obtain an intermediate; the intermediate (1 eq) was dissolved in tetrahydrofuran: water (1. ¹ H NMR(400MHz,CDCl ₃ )δ7.98(s,1H),7.32(s,1H),7.21(s,1H),4.10(s,2H),3.99(s,3H),3.97(s,3H),3.31(t,2H,J＝8.0Hz),2.87(t,2H,J＝8.0Hz).MS(EI):367.

33. Synthesis of Compound S33

1g (1 eq) of the compound was dissolved in N, N-dimethylformamide, and then O-hydroxyethylhydroxylamine hydrochloride (1.5 eq), TBTU (3 eq), and N, N-diisopropylethylamine (5 eq) were added in this order to react at room temperature overnight. After the reaction, the reaction mixture was poured into ice water, extracted with ethyl acetate, and the organic phase was collected and purified by column chromatography to obtain compound S33. ¹ H NMR(400MHz,CDCl ₃ )δ7.88(s,1H),7.32(s,1H),7.28(s,1H),3.97(s,3H),3.96(s,3H),3.72(t,2H,J＝8.4Hz),3.54(t,2H,J＝8.0Hz),3.30(t,2H,J＝8.0Hz),2.64(t,2H,J＝8.0Hz).MS(EI):353.

2. Cell screening experiment for activating interferon gene stimulating protein and promoting IFN-beta expression by compound

The detection method and the principle are as follows: THP1-Blue-ISG cells of human origin, into which IFN-. Beta.containing reporter system has been transferred, which induces the expression of downstream alkaline phosphatase, and the amount of which OD650 can be determined by a color reaction when alkaline phosphatase is secreted outside the cells. After the compound is added into the cells, if the interferon gene stimulating protein is activated, the expression of IFN-beta can be promoted, and further the increase of downstream alkaline phosphorylation secretion and the increase of the absorbance of a color reaction are promoted.

The test method comprises the following steps:

1. adding a compound: mu.L of a compound diluted with physiological saline was added to each well of a 96-well cell culture plate

The concentration of the compound was 100. Mu.M, with 2 replicate wells. The positive control compound was ADU-S100 at a concentration of 100. Mu.M. DMSO at 1% in 20. Mu.L of physiological saline was added to the non-medicated control group.

2. Adding cells: THP1-Blue-ISG cell count, adjusting cell concentration to 5X 10 ⁵ mL, add 180. Mu.l of cells per well for incubation. Thus, the final volume of each test well was 200. Mu.L, the DMSO content was 0.1%, and the test concentration of the compound was 10. Mu.M. The positive control compound is ADU-S100, the final concentration is 10 mu M, and the positive control compound is incubated for 24 hours for detection; another blank group was added with 180. Mu.L of culture solution.

3. And (3) detecting a color development reaction: after 24 hours, 20. Mu.l of the culture medium was transferred to a new 96-well plate, 200. Mu.l of color developing solution Quanti-Blue was added thereto, the plate was placed in an incubator at 37 ℃ and the OD650 value was measured after 0.5 to 2 hours.

4. Screening concentration of compound: 10 μ M.

5. And (4) analyzing results:

where Compound OD650 is the OD650 value of the Compound of the present invention, blank OD650 is the OD650 value of the medium, and Control OD650 is the OD650 value of the Control group without the Compound of the present invention (cells only and 0.1% DMSO).

6. And (4) evaluating the result: the activation multiple (Fold change) is more than or equal to 2.

The experimental results are as follows:

table 2 partial Compounds ability to activate human interferon gene stimulating protein in THP1 cells and promote type I interferon expression at 10. Mu.M concentration

Where CON represents the control without compound added (i.e. cell only and 0.1% DMSO).

The results show that at the concentration of 10uM, the compound in the patent can activate interferon gene stimulating protein and promote the expression of interferon factor IFN-beta; wherein, the agonistic activity of S10, S11, S12, S13, S19, S25 and S29 is equivalent to or even better than that of the cyclodiperidide compound ADU-S100 in phase I clinical research, and the application prospect is further promising.

Furthermore, the above compounds have 2.2 to 2.5 times enhanced agonistic activity relative to TW201817723A disclosing compound 1g (i.e., compound 16 therein).

TABLE 3 ability of Compounds S10 and S13 to activate human interferon gene stimulating protein in THP1-blue cells and promote type I interferon expression at different concentrations

Wherein CON represents the control without compound (i.e. cells only and 0.1% DMSO).

The above results show that the compounds S10 and S13 in this patent can activate interferon gene stimulating protein dose-dependently and promote the expression of interferon factor IFN-beta.

TABLE 4 ability of 10. Mu.M S10 and S13 to promote type I interferon expression in interferon gene-stimulated protein knock-out THP1-Dual cells

The above results show that the compounds S10 and S13 in this patent can not promote the expression of type I interferon in THP1-Dual cells with interferon gene stimulating protein knockout, which indicates that the compounds can promote the expression of interferon factor IFN-beta by activating interferon gene stimulating protein.

All documents mentioned in this application are incorporated by reference in this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes or modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the appended claims of the present application.

Claims

1. A compound of formula I, or a pharmaceutically acceptable salt thereof,

wherein,

R ¹ and R ² Independently selected from the group consisting of substituted or unsubstituted: halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C3-C8 cycloalkoxy;

the R is ¹ And R ² The substituent(s) in (b) means being independently substituted with one or more substituents selected from the group consisting of: halogen, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C3-C8 cycloalkoxy;

X ¹ and X ² Independently selected from the group consisting of: H. halogen;

X ³ selected from the group consisting of: o, S;

X ⁴ selected from the group consisting of: o, NR ⁵ 、S；

n is an integer selected from 0, 1,2, 3;

R ³ independently selected from the group consisting of substituted or unsubstituted: H. carboxyl, sulfonic acid group, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, 3-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, S, 3-8 membered heterocycloalkyl containing 1-3 heteroatoms selected from N, O, S;

R ⁴ and R ⁵ Independently selected from the group consisting of substituted or unsubstituted: H. carboxyl, sulfonic acid group, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, 3-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, S, 3-8 membered heterocycloalkyl containing 1-3 heteroatoms selected from N, O, S;

the R is ³ 、R ⁴ And R ⁵ The substituent(s) in (b) means being independently substituted with one or more substituents selected from the group consisting of: hydroxy, halogen, carboxy, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C12 alkoxy, C3-C8 cycloalkyl, C3-C8 cycloalkoxy, C6-C10 aryl, halogenated C6-C10 aryl, 3-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, S.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof,

X ¹ and X ² Independently selected from the group consisting of: H. fluorine;

X ³ selected from the group consisting of: o, S;

n is an integer selected from 1,2, 3;

R ¹ and R ² Independently selected from the group consisting of substituted or unsubstituted: halogen, C2-C6 alkenyl, C1-C6 alkoxy, C3-C8 cycloalkoxy;

the R is ¹ And R ² The substituent (b) means independently substituted with one or more substituents selected from the group consisting of: halogen, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C3-C8 cycloalkoxy.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof,

X ⁴ selected from the group consisting of: o, NR ⁵ ；

n is an integer selected from 1,2, 3;

R ⁴ and R ⁵ Independently selected from the group consisting of substituted or unsubstituted: H. carboxyl, sulfonic group, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, 3-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, S, containing3-8 membered heterocycloalkyl of 1-3 heteroatoms selected from N, O, S;

said R is ³ 、R ⁴ And R ⁵ The substituent(s) in (b) means being independently substituted with one or more substituents selected from the group consisting of: hydroxy, halogen, carboxy, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C12 alkoxy, C3-C8 cycloalkoxy, C2-C6 alkenyl, C6-C10 aryl, haloC 6-C10 aryl, 3-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, S.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

5. a process for preparing a compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

the method one comprises the following steps:

a-2) optionally reacting the compound of formula 3 with a lawson's reagent to provide a compound of formula 4;

wherein R is ¹ 、R ² 、R ³ 、R ⁴ 、X ¹ 、X ² 、X ⁴ N is as defined in claim 1;

the second method comprises the following steps:

wherein R is ¹ 、R ² 、R ³ 、R ⁴ 、X ¹ 、X ² 、X ³ 、X ⁴ N is as defined in claim 1, and R ² Is not a halogen.

6. A pharmaceutical composition, comprising:

(i) One or more therapeutically effective amounts of a compound of claim 1, or a pharmaceutically acceptable salt thereof; and

(ii) A pharmaceutically acceptable carrier.

7. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 6, for the preparation of a formulation for the prevention and/or treatment of a disease associated with type I interferon.

8. The use according to claim 7, wherein the type I interferon related diseases are selected from the group consisting of: breast cancer, ovarian cancer, liver cancer, melanoma, prostate cancer, colon cancer, and gastric cancer.

9. An interferon gene stimulating protein agonist comprising one or more compounds of claim 1, or a pharmaceutically acceptable salt thereof.